Subcutaneous injection is one of the most common routes of drug administration in laboratory mice, valued for its relative simplicity, moderate absorption rate, and lower stress profile compared to intravenous or intraperitoneal routes. For a standard 25-gram mouse, institutional guidelines generally cap the volume at about 0.25 mL per site using a 20-gauge needle, with no more than two to three injection sites used per day. But the apparent simplicity of the technique conceals a surprising amount of nuance in how the drug actually reaches the bloodstream, how the mouse experiences the procedure, and what happens to the tissue underneath the skin over days and weeks of repeated dosing.
Volume Limits and Needle Selection
The subcutaneous space in a mouse is limited, and overfilling it causes discomfort, poor absorption, and potential tissue damage. Widely referenced institutional guidelines recommend a maximum volume of 0.25 mL per injection site for a 25-gram mouse, which works out to 10 mL per kilogram of body weight. The recommended needle gauge is 20 G, though many labs use finer needles (25 G or 27 G) for smaller volumes to reduce tissue trauma. The guidelines also advise limiting subcutaneous administration to two or three sites per day to prevent excessive local stress on the tissue.1University of Iowa Office of Animal Resources. Substance Administration – Recommended Volumes (Informational Sheet) – Section: Recommended Maximum Volumes and Needle Sizes per Route, per Site, and per Species
These numbers are consensus figures drawn from published literature and set to maintain animal welfare. They are not absolute physiological limits. Some protocols deliver larger total daily volumes by splitting across multiple sites on the dorsum (the loose skin between the shoulder blades is the most common location). But exceeding the per-site recommendation risks forming a visible fluid bleb that absorbs slowly and can interfere with accurate dosing and pharmacokinetic measurements.
How Drugs Absorb After Subcutaneous Injection
Once injected under the skin, a drug enters the interstitial space, a loose connective-tissue compartment filled with extracellular fluid. From there, small molecules can diffuse directly into nearby blood capillaries and reach systemic circulation relatively quickly. Larger molecules, particularly proteins and antibodies, follow a different path: they are too big to cross capillary walls efficiently, so they drain into the lymphatic vessels that permeate the subcutaneous tissue and eventually empty into the venous system.
This dual-pathway absorption has practical consequences. Small-molecule drugs often show rapid uptake, sometimes with blood levels peaking within minutes. In one pharmacokinetic study in mice, the complement receptor antagonist PMX205 reached high bioavailability (above 90%) after subcutaneous administration and showed prolonged plasma and central nervous system exposure compared to intravenous, intraperitoneal, and oral routes at the same dose.2PubMed Central. Preclinical Pharmacokinetics of Complement C5a Receptor Antagonists PMX53 and PMX205 in Mice For that particular compound, subcutaneous delivery was essentially the best of both worlds: high total absorption and extended exposure.
Large biologic molecules can behave differently. A study of an IgG fusion protein found that subcutaneous injection in mice produced brain concentrations comparable to those achieved with intravenous injection, but with a much lower total plasma exposure than intraperitoneal dosing. The researchers concluded that subcutaneous injection was the preferred route for that fusion protein because it achieved therapeutic brain levels without the high systemic drug load seen with other routes.3PubMed Central. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice For both molecules, increasing the injection dose boosted the amount that reached circulation, a feature that matters when researchers need to push past a minimum effective concentration.
Lymphatic drainage of the injected material is not automatic. A study tracking fluorescent tracers after subcutaneous paw injection in mice found that efficient uptake into collecting lymphatic vessels occurred only after massage of the injection site. Without massage, larger polymer tracers remained stuck in the interstitial tissue with limited lymphatic transport. Smaller free dye, by contrast, was absorbed directly into the venous system within 30 seconds of injection.4The Journal of Clinical Investigation. Quantitative measurement of lymphatic function in mice by noninvasive near-infrared imaging of a peripheral vein – Section: Results This finding has real implications for researchers working with antibodies or nanoparticles: the rate at which a subcutaneous depot clears can depend heavily on local tissue handling and formulation size, not just the drug itself.
Stress and Welfare Considerations
Mice are not passive recipients of injections. The procedure triggers a measurable acute stress response, and the magnitude of that response depends on several factors, including the injection route, the mouse strain, and how the animal is handled before and after.
A study measuring plasma corticosterone, the primary stress hormone in mice, found that subcutaneous injection in the hindpaw caused a marked spike within 10 minutes in both C57BL/6 and BALB/c strains. The spike was present even in mice injected with vehicle alone, meaning the needle and handling contributed substantially to the stress response independent of whatever substance was being delivered. Strikingly, simply going through the motions of injection without actually inserting the needle also produced a significant corticosterone increase compared to unhandled mice.5European Journal of Pain. Plasma corticosterone levels in mouse models of pain – Section: Results The implication is clear: the stress of being restrained and manipulated is itself a significant confound in experiments, and researchers working with stress-sensitive endpoints need to account for it.
Strain differences matter here. In the same study, C57BL/6 mice showed a corticosterone peak that subsided within 30 minutes, while BALB/c mice stayed elevated longer and showed no difference between capsaicin and vehicle injection, suggesting their stress response was saturated by the handling alone. A separate telemetry study comparing injection routes found that heart rate, a sensitive real-time stress indicator, rose more sharply after intraperitoneal injection than after subcutaneous or intramuscular injection during sham procedures. However, this difference became inconsistent when saline was used as the injection fluid, suggesting that the substance being injected modifies the stress picture.6PubMed. Effect of restraint and injection methods on heart rate and body temperature in mice The technician’s experience level did not influence the stress response after subcutaneous injections, at least in the conditions tested.
How You Pick Up the Mouse Matters More Than the Needle
Handling method has an outsized effect on mouse welfare that persists long after any injection-related stress has faded. A study specifically designed to test whether the experience of subcutaneous injection would make mice fearful of their handlers found that it did not, as long as the handling method was itself non-aversive. Mice picked up using a tunnel (a small plastic tube placed in the cage) showed much more voluntary interaction with the handler and much less avoidance behavior than mice picked up by the tail. After receiving subcutaneous injections with brief immobilization, tunnel-handled mice showed no decrease in willingness to interact with the handler. Even after four additional daily injections, their behavior was unchanged.7Scientific Reports. Improving the practicality of using non-aversive handling methods to reduce background stress and anxiety in laboratory mice – Section: Experience of subcutaneous injection does not reverse effects of non-aversive handling
Tail-handled mice, by contrast, showed declining voluntary interaction over the same period, but this decline was not caused by the injections themselves. Control tail-handled mice who were merely picked up briefly without any injection showed the same low interaction levels. The handling method was the dominant variable; the injection was essentially invisible in the behavioral data. For researchers conducting repeated-dosing studies, this finding suggests that investing in tunnel or cup handling will do more for baseline welfare and data quality than worrying about the injection event itself.
Tissue Reactions at the Injection Site
The subcutaneous space tolerates most injections well, but certain formulations provoke local tissue reactions that can complicate long-term studies. A comparison of two sustained-release buprenorphine formulations in nude mice found that both produced a cystic lesion surrounded by a fibrous capsule at the injection site. One formulation (extended-release) induced more inflammatory infiltrates than the other, while the other (extended-release with a different carrier) maintained likely therapeutic plasma levels for a longer period with less local inflammation.8PubMed Central. Comparative Pharmacokinetics and Injection Site Histopathology in Nude Mice Treated with Long-acting Buprenorphine Formulations
Sustained-release meloxicam, an anti-inflammatory painkiller sometimes given subcutaneously for post-surgical analgesia, has also been associated with injection-site reactions. In BALB/cJ, C57BL/6J, and outbred CD1 mice, the sustained-release formulation produced redness and mass formation at the injection site. Histologically, these corresponded to necrotizing to pyogranulomatous panniculitis, a deep tissue inflammatory reaction. The inflammation was significantly greater in the sustained-release meloxicam group at both 7 and 14 days post-injection, and the character of the response did not change between those timepoints, meaning it was slow to resolve.9PubMed Central. Injection Reactions after Administration of Sustained-release Meloxicam to BALB/cJ, C57BL/6J, and Crl:CD1(ICR) Mice Researchers relying on sustained-release analgesics for welfare reasons need to weigh the benefit of less frequent dosing against the risk of creating a secondary inflammatory lesion that may itself cause discomfort or confound study endpoints.
Repeated Subcutaneous Dosing and Fibrosis
When the same subcutaneous site is injected repeatedly over weeks, the tissue can undergo fibrotic remodeling. This is not just a side effect to manage; it is actually the basis of a widely used disease model. The bleomycin-induced skin fibrosis model involves injecting bleomycin subcutaneously into the shaved back of mice every other day for four weeks. This protocol reproduces the skin fibrosis seen in systemic sclerosis, allowing researchers to quantify dermal thickness, collagen content, and inflammatory cell infiltration.10PubMed. Diminished induction of skin fibrosis in mice with MCP-1 deficiency After four weeks of daily bleomycin injections in wild-type C57BL/6 mice, the lesional dermis showed thickened collagen bundles, robust inflammation, and a shift from normal large-diameter collagen fibrils to abnormally small fibrils of about 42 nanometers in diameter.
For researchers not intending to model fibrosis, this finding serves as a caution: chronic subcutaneous injection protocols at the same site can alter skin architecture and inflammatory tone even with ostensibly benign substances, though the effect is far less dramatic than with a fibrogenic agent like bleomycin. Rotating injection sites and monitoring the skin for thickening or nodularity are standard practices in long-duration studies.
Depot Formulations and Sustained Release
One of the practical advantages of the subcutaneous route is that it supports depot formulations, where the drug is engineered to release slowly from the injection site over days or weeks. This reduces the number of injections an animal needs, which benefits both welfare and experimental consistency.
A GLP-1 and FGF21 dual-agonist fused to an elastin-like polypeptide linker demonstrated this approach in diabetic mice. The polypeptide linker acted as a sustained-release module, achieving zero-order (constant-rate) drug release. Once-weekly subcutaneous injection produced potent weight-reducing effects and improved blood sugar control that neither agonist achieved alone.11PubMed Central. Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia The key engineering challenge with depot formulations is controlling the release rate while avoiding the tissue reactions described earlier. Lipid-based depot technologies such as DepoFoam encapsulation have been shown to sustain drug release from days to weeks after subcutaneous administration, with the release rate tunable through changes in lipid and aqueous composition.12PubMed. A lipid based depot (DepoFoam technology) for sustained release drug delivery
Particle size also plays a role. A study of a candidate drug administered subcutaneously to rodents as drug particles found that reducing particle size to nanosuspensions improved systemic exposure. However, the formulation interacted with hepatic recirculation, meaning the drug cycled through the liver after absorption, complicating the plasma profile.13PubMed. A candidate drug administered subcutaneously to rodents as drug particles showing hepatic recirculation which influenced the sustained release process Multiple overlapping processes driving the plasma curve is a common headache in subcutaneous pharmacokinetics, and it underscores why intravenous injection, despite its technical difficulty, remains the gold standard when researchers need a clean absorption profile.
Subcutaneous Fluid Therapy in Sick Mice
Subcutaneous injection is not limited to drug delivery. In veterinary and research settings, it is routinely used to rehydrate mice that are losing fluids due to illness. Warmed balanced salt solution is injected under the loose skin of the back, forming a visible fluid pocket that absorbs over the next several hours. Guidelines generally recommend warming the solution to about 37.7 °C before injection and alternating injection sites when large volumes are needed to prevent skin tension.14PubMed Central. A Review on In Vivo Research Dehydration Models and Application of Rehydration Strategies – Section: Subcutaneous (SC) Injection The maximum recommended dose per site is typically around 5 mL per kilogram.
A dramatic demonstration of this approach came from a study of knockout mice lacking the IL-22 gene, which die from infection with the intestinal pathogen Citrobacter rodentium. When infected knockout mice received daily subcutaneous injections of balanced salt solution starting at 5 days post-infection, their serum dehydration markers normalized. Renin and corticosterone levels, both elevated by infection, dropped significantly with fluid therapy. Most remarkably, the rehydrated mice survived completely, proving that dehydration, not the infection itself, was the primary cause of death in this model.15Nature Communications. Rehydration rescues Il22−/− mice from lethal Citrobacter rodentium infection – Section: Dehydration drives mortality in Il22 −/− mice following C. rodentium infection That finding reshaped the interpretation of a well-studied infection model and illustrates how subcutaneous fluid support can be the difference between losing an entire experimental cohort and keeping animals alive through a critical illness window.
Subcutaneous Injection in Tumor Models
Oncology research relies heavily on subcutaneous tumor implantation. Researchers inject cancer cell suspensions or tissue fragments under the skin of immunocompromised or syngeneic mice to grow tumors that can be measured externally with calipers. This approach is favored for its accessibility: the tumor sits right beneath the skin surface, making it easy to monitor growth, measure volume, and assess treatment responses without imaging equipment.
A comparison of subcutaneous versus orthotopic (anatomically correct site) implantation of 4T1-luc2 breast cancer cells in BALB/c mice found that both methods generated tumors, but the two approaches produced different growth dynamics, metastatic patterns, survival curves, and histopathological features.16PubMed Central. Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation Subcutaneous tumors grow in an artificial microenvironment, surrounded by skin connective tissue rather than the mammary fat pad where breast cancers normally arise. This trade-off between convenience and biological relevance is a persistent tension in preclinical oncology. Subcutaneous models are the standard first screen for drug efficacy, but findings often require validation in orthotopic models before advancing.
Post-Surgical Pain Management via Subcutaneous Delivery
Subcutaneous injection is the standard route for administering analgesics before and after surgery in mice. Local anesthetics like lidocaine and bupivacaine can be injected subcutaneously at the incision site to provide wound-area pain relief. A study evaluating subcutaneous infiltration of lidocaine, bupivacaine, and their combination before mouse laparotomy found that combining the two drugs at specific doses provided adequate analgesia in the early hours after surgery, with better recovery compared to single-agent groups.17Journal of Surgical Research and Reviews. Grimace scaling after mouse laparotomy with various doses of lidocaine, bupivacaine, and a combination of lidocaine/bupivacaine in post-surgical analgesia
For systemic analgesia, drugs like buprenorphine and meloxicam are typically given subcutaneously in the scruff region. The choice between standard and sustained-release formulations involves a trade-off: standard formulations require dosing every 6 to 12 hours, increasing handling frequency, while sustained-release formulations reduce handling but can cause the tissue reactions described earlier. A study comparing multimodal analgesia regimens with high-dose NSAID monotherapy after neurosurgery in mice found that the multimodal approach was not clearly superior to NSAID-only treatment, suggesting that simpler analgesic protocols delivered subcutaneously can perform as well as more complex combinations.18Scientific Reports. Refining pain management in mice by comparing multimodal analgesia and NSAID monotherapy for neurosurgical procedures – Section: Discussion
Skin Thickness Variation and Why It Matters
Mouse skin is not uniform. Measurements of hind limb skin thickness across individual mice have shown a range from roughly 212 to 531 micrometers, with substantial variation in both thickness and mechanical properties even within a small sample.19PubMed Central. Natural Variation in Skin Thickness Argues for Mechanical Stimulus Control by Force Instead of Displacement This matters because the boundary between a true subcutaneous injection and an inadvertent intradermal injection depends on how deep the needle goes relative to the skin. A shallow insertion through thin skin can deposit fluid in the wrong compartment, altering both absorption kinetics and the local immune response. Researchers working with particularly thin-skinned strains or very young mice sometimes switch to shorter needles or adjust their angle of insertion to avoid intradermal deposition.
Needle-Free Alternatives
Jet injectors, which use a high-pressure fluid stream to penetrate the skin without a needle, have been tested as an alternative to conventional subcutaneous injection in mice. In a hepatitis B vaccination study, mice immunized intradermally via jet injector showed immune responses comparable to those achieved with subcutaneous needle injection at day 47, with no adverse events beyond minor bleeding at the injection site in a few animals across both methods.20PubMed. Delivery of immunoreactive antigen using a controllable needle-free jet injector
A head-to-head comparison of inactivated rabies vaccine delivered by intraperitoneal, intramuscular, subcutaneous, and needle-free intradermal routes in mice found that the intradermal jet-injection route actually outperformed all others. It produced the highest antibody titers, elicited a balanced immune response, and provided the best protection against lethal viral challenge. A one-third dose delivered intradermally by jet injector matched or exceeded a full dose given subcutaneously.21PubMed Central. Immune Response of Inactivated Rabies Vaccine Inoculated via Intraperitoneal, Intramuscular, Subcutaneous and Needle-Free Injection Technology-Based Intradermal Routes in Mice The superior performance of intradermal delivery was linked to longer local retention of antigen at the injection site and higher lymphatic drainage, both of which play to the skin’s dense network of immune cells. For vaccine studies specifically, needle-free intradermal delivery is emerging as a compelling alternative that may reduce both animal stress and required antigen doses, though the equipment remains more specialized and expensive than a syringe.